Molecular Partners AG ADR (MOLN)
NASDAQ: MOLNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 7, 4:00 PM ET
MOLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $145.94M
- EPS (TTM)
- -$1.71
- Dividend yield
- None
- 52-week range
- 3.53 – 5.36
- Day range
- 3.81 – 3.81
- Volume / Avg
- 87 / 1.18K
- Beta
- —
- Shares outstanding
- 38.31M
- Next earnings
- Oct 29, 2026
52-week range
MOLN stock today
Molecular Partners (MOLN) is trading at $3.81 on Oct 7, essentially unchanged from the prior close, versus the S&P 500's 0.25% decline. At this level, MOLN sits near the bottom of its 52-week range of $3.53 to $5.36: 28.9% below the high, set on Feb 27, 2026 and 7.9% above the low. MOLN is down 12.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 2.7%.
Molecular Partners has posted a net loss over the last twelve months (EPS of -$1.71), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 29 before the market opens; analysts expect EPS of -$0.46.
Summary generated from market data by MetaCap's automated system. Methodology
About Molecular Partners
Company profileMolecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Patrick Amstutz Ph.D.
- Headquarters
- Schlieren
- Employees
- 134
- IPO year
- 2021
- Website
- molecularpartners.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$10.37+172.18%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $-0.46
Molecular Partners peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VYGRVoyager Therapeutics Inc. | 2.36 | -4.66% | $145.11M | vs MOLN |
| ABOSAcumen Pharmaceuticals Inc. | 2.05 | -2.62% | $147.89M | vs MOLN |
| TARAProtara Therapeutics Inc. | 2.52 | -2.70% | $148.92M | vs MOLN |
| AVXLAnavex Life Sciences Corp. | 1.52 | -0.98% | $140.44M | vs MOLN |
| CHRSCoherus Oncology Inc. | 0.9831 | -2.66% | $151.89M | vs MOLN |
| OTLKOutlook Therapeutics Inc. | 0.5746 | -2.61% | $139.88M | vs MOLN |
| ARMPArmata Pharmaceuticals Inc. | 3.68 | -3.41% | $136.83M | vs MOLN |
| CRDLCardiol Therapeutics Inc. Class A | 1.34 | +1.14% | $162.22M | vs MOLN |
Indexes, lists and sector
Molecular Partners stock FAQ
What is Molecular Partners's stock price today?
MOLN last traded at $3.81 as of Oct 7, 4:00 PM EDT, up 0.00% on the day. Prices are delayed at least 15 minutes.
When is Molecular Partners's next earnings date?
Molecular Partners is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $-0.46.
Who is Molecular Partners's CEO?
Dr. Patrick Amstutz Ph.D. is the chief executive officer of Molecular Partners AG ADR, which has about 134 employees.
What is the MOLN 52-week high?
The 52-week high for MOLN is $5.36 and the 52-week low is $3.53. The stock is currently 28.9% below its high.